Ren Ji-Lian, Cui Ling-Zhi, Hao Xiao-Xia, Li Xiao-Yan
Department of Medical Laboratory, Fenyang College of Shanxi Medical University, Fenyang 032200, Shanxi Province, China.E-mail:
Department of Cadre Diagnosis and Treatment, Shanxi Provincial Cancer Hospital, Taiyuan 030013, Shanxi Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Feb;31(1):115-119. doi: 10.19746/j.cnki.issn.1009-2137.2023.01.018.
To analyze the relationship between microRNA (miR)-21, miR-191 and clinical stage of patients with diffuse large B-cell lymphoma (DLBCL).
100 patients with DLBCL treated in Shanxi Fenyang Hospital from January 2019 to January 2021 were selected as the research subjects. All patients was divided into stage I, stage II, stage III and stage IV according to Ann-Arbor (Cotswolds) staging system at admission. The baseline data of patients at different clinical stages were counted and compared in detail. The relationship between the levels of miR-21 and miR-191 and the clinical stage of DLBCL patients was mainly analyzed.
Among the 100 patients with DLBCL, there were 15 patients at stage I, 25 patients at stage II, 37 patients at stage III and 23 patients at stage IV. The levels of miR-21 and miR-191 in patients at stage Ⅰ, Ⅱ, Ⅲ and Ⅳ were increased gradually, which showed statistically significant differences (<0.05). According to Kendall's tau-b correlation analysis, it was found that the levels of miR-21 and miR-191 were positively correlated with the clinical stage of DLBCL patients (=0.566, 0.636). Multiple logistic regression analysis showed that the overexpression of serum miR-21 and miR-191 was a risk factor for high clinical stage in patients with DLBCL (OR>1, <0.05). Bivariate Pearson correlation analysis showed that there was a positive correlation between miR-21 and miR-191 levels in patients with DLBCL (=0.339).
The overexpression of miR-21 and miR-191 in patients with DLBCL is related to high clinical stage.
分析微小RNA（miR）-21、miR-191与弥漫性大B细胞淋巴瘤（DLBCL）患者临床分期的关系。
选取2019年1月至2021年1月在山西汾阳医院接受治疗的100例DLBCL患者作为研究对象。所有患者入院时根据Ann-Arbor（Cotswolds）分期系统分为Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期。详细统计并比较不同临床分期患者的基线数据。主要分析miR-21和miR-191水平与DLBCL患者临床分期的关系。
100例DLBCL患者中，Ⅰ期15例，Ⅱ期25例，Ⅲ期37例，Ⅳ期23例。Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者的miR-21和miR-191水平逐渐升高，差异有统计学意义（<0.05）。根据Kendall's tau-b相关性分析，发现miR-21和miR-191水平与DLBCL患者的临床分期呈正相关（=0.566，0.636）。多因素logistic回归分析显示，血清miR-21和miR-191过表达是DLBCL患者临床分期高的危险因素（OR>1，<０.０５）。双变量Pearson相关性分析显示，DLBCL患者miR-21和miR-191水平呈正相关（=0.339）。
DLBCL患者中miR-21和miR-191的过表达与临床分期高有关。
